根治性前列腺切除术后PSMA-PET引导挽救性放疗的复发或持续前列腺癌患者的最大标准化摄取值:一项多中心回顾性分析
本研究为多中心回顾性分析,纳入235例在挽救性放疗前接受68Ga-PSMA11-PET且PET阳性局限于盆腔局部复发和/或淋巴结复发的患者,中位随访24个月,2年和4年生化复发无生存率分别为68%和56%。局部复发病灶SUVmax≥75%四分位数与不良生化复发无生存显著相关(P=0.022,HR 2.1,95%CI 1.1-4.6),淋巴结复发病灶SUVmax与生化复发无生存无显著关联。
要点
- 局部复发病灶SUVmax≥75%四分位数与不良生化复发无生存显著相关(P=0.022,HR 2.1,95%CI 1.1-4.6)。
- 淋巴结复发病灶SUVmax与生化复发无生存无显著关联。
- 局部复发病灶SUVmax在多因素分析中仍显著(P=0.030)。
核心结论
- 无创生物标志物SUVmax可对接受挽救性放疗且PSMA-PET显示复发局限于前列腺窝的患者进行预后判断。
- SUVmax的加入可能有助于改善复发前列腺癌患者的风险分层,并在治疗强化或降阶梯方面指导个体化治疗决策。
研究设计与样本
- 回顾性多中心研究,纳入四家高容量中心在挽救性放疗前接受68Ga-PSMA11-PET的患者。
- 仅纳入PET阳性且局限于盆腔的局部复发和/或淋巴结复发患者,最终队列235例,中位随访24个月。
- 患者接受前列腺窝调强挽救性放疗,淋巴结病变者行选择性淋巴引流区照射,PET阳性局部复发和淋巴结复发行剂量递增,雄激素剥夺治疗由主治医师决定。
- 局部复发和淋巴结复发手动勾画并提取SUVmax,采用Cox回归分析临床参数及SUVmax相关值对生化复发无生存的影响。
主要发现
- 全部患者2年和4年生化复发无生存率分别为68%和56%。
- 局部复发存在与有利的生化复发无生存相关(p=0.016),淋巴结复发存在与不良生化复发无生存相关(p=0.007)。
- 局部复发病灶SUVmax≥中位数有趋势(p=0.071),SUVmax≥75%四分位数与不良生化复发无生存显著相关(p=0.022,HR 2.1,95%CI 1.1-4.6)。
- 淋巴结复发病灶SUVmax与生化复发无生存无显著关联。
- 局部复发病灶SUVmax在多因素分析中仍显著(p=0.030);随访>12个月患者(n=197)的敏感性分析证实上述结果。
关键数值与推荐
- 全部患者2年生化复发无生存率为68%,4年为56%。
- 局部复发病灶SUVmax≥75%四分位数:p=0.022,HR 2.1,95%CI 1.1-4.6。
- 局部复发病灶SUVmax多因素分析:p=0.030。
- 淋巴结复发病灶SUVmax与生化复发无生存无显著关联。
临床怎么用
- 作者认为SUVmax的加入可能有助于改善复发前列腺癌患者的风险分层。
- 作者认为SUVmax可能有助于在治疗强化或降阶梯方面指导个体化治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aims to evaluate the association of the maximum standardized uptake value (SUVmax) in positron-emission tomography targeting prostate-specific membrane antigen (PSMA-PET) prior to salvage radiotherapy (sRT) on biochemical recurrence free survival (BRFS) in a large multicenter cohort. METHODS: Patients who underwent 68 Ga-PSMA11-PET prior to sRT were enrolled in four high-volume centers in this retrospective multicenter study. Only patients with PET-positive local recurrence (LR) and/or nodal recurrence (NR) within the pelvis were included. Patients were treated with intensity-modulated-sRT to the prostatic fossa and elective lymphatics in case of nodal disease. Dose escalation was delivered to PET-positive LR and NR. Androgen deprivation therapy was administered at the discretion of the treating physician. LR and NR were manually delineated and SUVmax was extracted for LR and NR. Cox-regression was performed to analyze the impact of clinical parameters and the SUVmax-derived values on BRFS. RESULTS: Two hundred thirty-five patients with a median follow-up (FU) of 24 months were included in the final cohort. Two-year and 4-year BRFS for all patients were 68% and 56%. The presence of LR was associated with favorable BRFS (p = 0.016). Presence of NR was associated with unfavorable BRFS (p = 0.007). While there was a trend for SUVmax values ≥ median (p = 0.071), SUVmax values ≥ 75% quartile in LR were significantly associated with unfavorable BRFS (p = 0.022, HR: 2.1, 95%CI 1.1-4.6). SUVmax value in NR was not significantly associated with BRFS. SUVmax in LR stayed significant in multivariate analysis (p = 0.030). Sensitivity analysis with patients for who had a FU of > 12 months (n = 197) confirmed these results. CONCLUSION: The non-invasive biomarker SUVmax can prognosticate outcome in patients undergoing sRT and recurrence confined to the prostatic fossa in PSMA-PET. Its addition might contribute to improve risk stratification of patients with recurrent PCa and to guide personalized treatment decisions in terms of treatment intensification or de-intensification. This article is part of the Topical Collection on Oncology-Genitourinary.
引用
- Spohn SKB, Farolfi A, Schandeler S, et al. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis. Eur J Nucl Med Mol Imaging. 2022. PMID: 35984452. doi:10.1007/s00259-022-05931-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。